



# Prolia® or Forteo® Prior Authorization Form

**Maryland Medicaid  
Pharmacy Program**  
Fax: (866) 440-9345  
Phone: (800) 932-3918

**Patient's Information:**

DATE: \_\_\_\_\_  
 NAME: \_\_\_\_\_ DOB: \_\_\_\_\_  
 Recipient's Maryland Medicaid Number: \_\_\_\_\_ SEX:  M  F

**Prescriber's Information:**

NAME: \_\_\_\_\_ NPI # \_\_\_\_\_  
 Phone # \_\_\_\_\_ Fax # \_\_\_\_\_

**Contact Person for this Request:**

NAME: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

Y	N	<b>FORTEO®</b>
<input type="checkbox"/>	<input type="checkbox"/>	Does the patient have a diagnosis of primary or hypogonadal osteoporosis in men OR postmenopausal osteoporosis in women?
<input type="checkbox"/>	<input type="checkbox"/>	Does the patient have a diagnosis of glucocorticoid-induced osteoporosis with daily use of > prednisone 5mg daily (or equivalent) for at least 3 months?
<input type="checkbox"/>	<input type="checkbox"/>	Does the patient have any of the following contraindications/exclusions to Forteo® therapy? (Paget's disease, prior external beam or implant radiation therapy involving the skeleton, bone metastases, skeletal malignancies, metabolic bone diseases other than osteoporosis, hypercalcemia or unexplained elevations in alkaline phosphatase)
<input type="checkbox"/>	<input type="checkbox"/>	Has the patient experienced treatment failure with bisphosphonates (i.e. alendronate, etidronate, ibandronate, risendronate)?
<input type="checkbox"/>	<input type="checkbox"/>	Is the use of bisphosphonate therapy contraindicated?
<input type="checkbox"/>	<input type="checkbox"/>	Is the patient receiving at a minimum both calcium 1000 mg and vitamin D 400 IU daily?
<input type="checkbox"/>	<input type="checkbox"/>	Is the request for more than 20 mcg per day?
<input type="checkbox"/>	<input type="checkbox"/>	The duration of treatment will be/is no longer than 2 years during a patient's lifetime.

**Directions for use:**

Y	N	<b>PROLIA®</b>
<input type="checkbox"/>	<input type="checkbox"/>	Has the patient experienced treatment failure with bisphosphonates (i.e. alendronate, etidronate, ibandronate, risendronate)?
<input type="checkbox"/>	<input type="checkbox"/>	Is the use of bisphosphonate therapy contraindicated?
<input type="checkbox"/>	<input type="checkbox"/>	Does the patient have a diagnosis of breast cancer?
<input type="checkbox"/>	<input type="checkbox"/>	Is the patient receiving an Aromatase Inhibitor Therapy (anastrozole, exemestane, letrozole)?
<input type="checkbox"/>	<input type="checkbox"/>	Does the patient have a diagnosis of non-metastatic prostate cancer?
<input type="checkbox"/>	<input type="checkbox"/>	Is the patient receiving an Androgen Deprivation Therapy (leuprolide, goserelin, triptorelin, histrelin, degarelix, abiraterone, flutamide, bicalutamide, nilutamide, ketoconazole, enzalutamide, etc.)?
<input type="checkbox"/>	<input type="checkbox"/>	Does the patient have any contraindications to Prolia® therapy (hypocalcaemia, pregnancy, hypersensitivity to components)?
<input type="checkbox"/>	<input type="checkbox"/>	Is the patient receiving at a minimum both calcium 1000 mg and vitamin D 400 IU daily?
<input type="checkbox"/>	<input type="checkbox"/>	Is the request for more than one 60 mg/ml injection per 6 months?
<input type="checkbox"/>	<input type="checkbox"/>	Has the patient had 6 or more paid claims for Prolia®?

**Directions for use:**

I certify that the above information is accurate and will be made available for audit, if requested.

Prescriber's Signature \_\_\_\_\_ Date \_\_\_\_\_

**Fax this completed form to 866-440-9345. Incomplete forms will not be reviewed.**